




- (51) **International Patent Classification:**
C07K 14/705 (2006.01) *A61K 47/64* (2017.01)
- (21) **International Application Number:**
PCT/US2023/014302
- (22) **International Filing Date:**
01 March 2023 (01.03.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/315,529 01 March 2022 (01.03.2022) US
63/330,120 12 April 2022 (12.04.2022) US
63/353,896 21 June 2022 (21.06.2022) US
- (71) **Applicant:** **CROSSLINK THERAPEUTICS INC.**
[US/US]; 244 Pearl Street, Cambridge, Massachusetts
02139 (US).
- (72) **Inventors:** **CHAPARRO, Rodolfo, J.**; c/o Crosslink Therapeutics Inc., 244 Pearl Street, Cambridge, Massachusetts 02139 (US). **SEIDEL, Ronald, D., III**; c/o Crosslink Therapeutics Inc., 244 Pearl Street, Cambridge, Massachusetts 02139 (US).
- (74) **Agent:** **RICIGLIANO, Joseph, W.**; Hoffmann & Baron LLP, 6900 Jericho Turnpike, Syosset, New York 11791 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** ATP-DEPENDENT AGONISTS OF IMMUNE CELLS FUNCTION AS ANTICANCER AGENTS

FIG. 1



(57) **Abstract:** The present disclosure provides polypeptide constructs that act as agonists of immune cell function when exposed to sufficient levels of ATP to cause their assembly into dimers or higher level complexes (e.g., trimers, tetramers, etc.). The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cell and/or NK cells) that function to promote anti-tumor immune responses. The constructs may be employed as anti-cancer agents/therapeutics for the treatment of solid tumors that have elevated levels of ATP.

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*